Financing ·
CAMP4 Therapeutics Corporation received regulatory clearance from Australia's Therapeutic Goods Administration and…
CAMPCamp4 Therapeutics Corp
CAMP4 Therapeutics Corporation received regulatory clearance from Australia's Therapeutic Goods Administration and local Human Research Ethics Committee to initiate a Phase 1/2 clinical trial of CMP-002 for SYNGAP1-related disorder. This regulatory milestone satisfies a condition in the company's September 2025 Securities Purchase Agreement, making the company eligible to receive up to $50.1 million in gross proceeds from a second closing of a private placement in exchange for up to 32,721,172 shares of common stock or pre-funded warrants. The second closing is expected to occur on or about August 3, 2026. CAMP4 Therapeutics is a clinical-stage biopharmaceutical company developing RNA-targeting therapeutics for genetic diseases.